COSCIENS Biopharma, Inc. (formerly Aeterna Zentaris, Inc.) (SC)
Address: 315 Sigma Drive, Suite 302D
City: Summerville
State: SC
Zip: 29486
County: Berkeley
Country: USA
Website: https://www.cosciensbio.com/
Phone: (843) 900-3223
NAICS: 325414 - Biological Product (except Diagnostic) Manufacturing
Parent Company Country of Origin: Canada
Industries: Life Sciences, Pharmaceutical, & Biotech
Approximate Employment: 1-10
Type of Operation: Research & Development
Business Classification: No Classification Listed
Is SourceSC Company: No
Product Description: COSCIENS Biopharma Inc. is the result of a merger between Aeterna Zentaris and Ceapro Inc. Therefore, neither Aeterna Zentaris nor Ceapro Inc. can be considered the parent company of COSCIENS Biopharma Inc. The merger occurred in June 2024, and the company's name change to COSCIENS Biopharma Inc. was announced in August 2024. COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS' lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Return to company search
Data is based on company's response to SC Industry Survey, news sources or other research. Submit changes to this record.